Aim

The aim of this report was to investigate the available body of evidence for the treatment and prognosis of ME/CFS as well as a review of the health care experi­ences of patients.

Background

Myalgic encephalomyelitis, also called Chronic Fatigue syndrome (ME/CFS), was first described 70 years ago. The disorder often is preceded by an infection but the pathology and mechanisms behind ME/CFS are still unknown. People with ME/CFS can suffer from a broad spectrum of symptoms, e.g. prolonged fatigue, pain and post-exertional malaise (PEM). Individuals with ME/CFS have decreased activity levels and can have difficulty handling their everyday day duties, work, or studies and maintaining social relationships. For some, the symptoms can be so severe that they are home- or bedbound.

There are no bio markers for ME/CFS that can be used for diagnosis. The criteria for diagnosis have therefore developed over the years and are consensus-based sets of core symptoms. All the criteria include newly-onset severe and persistent fatigue and stipulate that core symptoms must have persisted for at least 6 months. The newer Canadian Consensus Criteria differs from previous criteria in that PEM lasting at least 24 hours after physical or mental exertion is required for a diagnosis. By applying the Canadian Consensus Criteria, the prevalence of ME/CFS is estimated to be about 0,1% of the population.

Differentiating between ME/CFS and other diseases with long lasting fatigue, e.g. stress related exhaustion disorder, can be difficult. Studies show that half of patients referred to specialist clinics for suspicion of ME/CFS were shown to have other diseases after closer examination, mostly sleep or psychiatric disorders.

There is no curative treatment for ME/CFS. Health care therefore aims at relieving symptoms and supporting the patients in the management of their every­day lives.

Content of the report

This report is made up of four systematic reviews, conducted according to international guidelines. The first systematic review focuses on treatments and their effects on fatigue and PEM for persons with ME/CFS diagnosed with the Canadian Consensus Criteria. Treatments that aimed at relieving other symptoms, e.g. sleep problems or pain, or psychological therapies aimed at helping patients manage their disease were not included. Included studies were controlled clinical trials, with or without randomisation.

The second systematic review assesses prognosis for recovery and return to work, while the third investigates whether there are any prognostic factors for im­provement and return to work. In the fourth systematic review, we explore how patients experience their health care by reviewing studies that used qualitative methods, such as interviews, to address this question.

The report only includes studies on adults.

Main results

A major finding was that the effects of treatments for patients diagnosed with the Canadian Consensus Criteria on fatigue or PEM cannot be estimated. Most studies used older criteria, mainly the Fukuda criteria, meaning there is a risk that the participants in the studies had other conditions, such as stress related exhaustion dis­order or depression. Whether these results are valid for persons diagnosed according to the Canadian Consensus Criteria is there­fore unclear.

A small number of studies, most investigating pharma­ceutical treatments, used the Canadian Consensus Criteria. None of these studies reported that the drug reduced fatigue.

The prognostic studies identified applied older criteria. Two studies conducted in Scandinavian countries reported that a substantial proportion of the participants had not recovered at follow-up, around 10 years after symptom onset. One English and one Norwegian study found that many patients who had been diagnosed in specialist clinics after several years of disease and unemployment, had not yet returned to work or study at follow-ups conducted many years later. Prognostic factors for recovery or return to work could not be evaluated as there were few studies, which were small and had substantial methodological limitations.

The qualitative studies mostly described patient experiences in primary care. Many perceived that getting a diagnosis was a milestone and that individually tailored support was crucial for them to move on with their lives. They experienced the process of obtaining a diagnosis as burdensome and frustrating and felt that they were met with ignorance and lack of understanding.

Discussion

This report shows that there are many scientific evid­ence gaps regarding ME/CFS. Many gaps, such as methods for diagnosis and efficacy of curative or disease modifying treatments, are related to the lack of understanding of the aetiology behind ME/CFS.

This report also indicates that a thorough diagnostic work-up is crucial. Multidisciplinary specialist competences are necessary to reliably exclude other disorders.

Finally, the absence of evidence for effect of ME/CFS treatments does not mean that the treatments lack effect, but rather indicates that research is needed to clarify the effects of current treatments for people diagnosed with ME/CFS according to the Canadian Consensus Criteria. Meanwhile, it is important to support people with ME/CFS so they can attain the best quality of life, levels of function and participation in society as is possible. Since ME/CFS is relatively uncommon compared to other similar disorders, e.g. stress related exhaustion disorder or chronic pain, specialist clinics for ME/CFS would probably be advantageous, as they would be most likely to be able to closely follow the research and quickly implement new developments into clinical practice.

The full report in Swedish

The full resport in Swedish "/en/publications/sbu-bereder/myalgic-encephalomyelitis-and-chronic-fatigue-syndrome-mecfs/"

Flow charts

Figure 4.1

Flow chart of the literature review regarding the effect of treatments

Reference list of full report

1.

Acheson ED. Benign myalgic encephalomyelitis. Lancet. 1957;272:834–5. [PubMed: 13417614]

2.

Galpine JF, Brady C. Benign myalgicencephalomyelitis. Lancet. 1957;272:757–8. [PubMed: 13417586]

3.

Holmes GP, Kaplan JE, Gantz NM, Komaroff AL, Schonberger LB, Straus SE, et al. Chronic Fatigue Syndrome: aworking case definition. Ann Intern Med. 1988:387–9. [PubMed: 2829679]

4.

Committee on the Diagnostic Criteriafor Myalgic Encephalomyelitis/ChronicFatigue Syndrome; Board on the Healthof Select Populations; Institute of Medicine. Beyond myalgic encephalomyelitis/chronic fatigue syndrome: Redefining anillness. Washington, DC: The NationalAcademies; 2015.

5.

White P. What causes prolonged fatigueafter infectious mononucleosis: and doesit tell us anything about chronic fatiguesyndrome? J Infect Dis. 2007;196:4–5. [PubMed: 17538875]

6.

Borsini A HN, Mondelli V, Chalder T, Pariante CM. Childhood stressors inthe development of fatigue syndromes:a review of the past 20 years of research. Psychol Med. 2014;44:1809–23. [PubMed: 24093427]

7.

Leone SS, Wessely S, Huibers MJ, Knottnerus JA, Kant I. Two sides of thesame coin? On the history and phenomenology of chronic fatigue and burnout. Psychol Health. 2011;26:449–64. [PubMed: 20437294]

8.

Stormorken E JL, Kirkevold M. Factors impacting the illness trajectoryof post-infectious fatigue syndrome: aqualitative study of adults’ experiences. BMC Public Health. 2017;17:952. [PMC free article: PMC5729235] [PubMed: 29237442]

9.

Engel G. The need for a new medicalmodel: A challenge for biomedicine. Science. 1977;196:129–36. [PubMed: 847460]

10.

Geraghty KJ, Blease C. Myalgic encephalomyelitis/chronic fatigue syndrome andthe biopsychosocial model: a review ofpatient harm and distress in the medicalencounter. Disabil Rehabil. 2018:1–10. [PubMed: 29929450]

11.

Blomberg J, Gottfries CG, Elfaitouri A, Rizwan M, Rosen A. Infection elicitedautoimmunity and myalgic encephalomyelitis/chronic fatigue syndrome:An explanatory model. Front Immunol. 2018;9:229. [PMC free article: PMC5818468] [PubMed: 29497420]

12.

Schutzer SE, Angel TE, Liu T,Schepmoes AA, Clauss TR, Adkins JNet al. Distinct cerebrospinal fluid proteomes differentiate post-treatment lyme disease from chronic fatigue syndrome. In: PLoS One; 2011. [PMC free article: PMC3044169] [PubMed: 21383843]

13.

Moneghetti KJ, Skhiri M, Contrepois K, Kobayashi Y, Maecker H, Davis M, et al. Value of circulating cytokine profiling during submaximal exercise testing in myalgic encephalomyelitis/chronic fatigue syndrome. Sci Rep. 2018;8:2779. [PMC free article: PMC5807550] [PubMed: 29426834]

14.

Fluge O, Mella O, Bruland O, Risa K, Dyrstad SE, Alme K, et al. Metabolic profiling indicates impaired pyruvate dehydrogenase function in myalgic encephalopathy/chronic fatigue syndrome. JCI Insight. 2016;1:e89376. [PMC free article: PMC5161229] [PubMed: 28018972]

15.

Siessmeier T NW, Hardt J, Schreckenberger M, Egle UT, Bartenstein P. Observer independent analysis of cerebral glucose metabolism in patients with chronic fatigue syndrome. J Neurol Neurosurg Psychiatry. 2003;74:922–8. [PMC free article: PMC1738575] [PubMed: 12810781]

16.

Nakatomi Y MK, Ishii A, Wada Y, Tanaka M, Tazawa S, Onoe K, et al. Neuroinflammation in patients with chronic fatigue syndrome/myalgic encephalomyelitis: An ¹¹C-(R)-PK11195 PET Study. J Nucl Med. 2014;55:945–50. [PubMed: 24665088]

17.

Elfaitouri A HB, Bölin-Wiener A, Wang Y, Gottfries CG, Zachrisson O, Pipkorn R, et al. Epitopes of microbial and human heat shock protein 60 and their recognition in myalgic encephalomyelitis. PLoS One. 2013:8. [PMC free article: PMC3842916] [PubMed: 24312270]

18.

Loebel M GP, Heidecke H, Bauer S, Hanitsch LG, Wittke K, et al. Antibodies to beta adrener-gic and muscarinic cholinergic receptors in patients with Chronic Fatigue Syndrome. Brain Behav Immun. 2016;52:32–9. [PubMed: 26399744]

19.

Scheibenbogen C LM, Freitag H, Krueger A, Bauer S, Antelmann M, et al. Immunoadsorption to remove ß2 adrenergic receptor antibodies in Chronic Fatigue Syndrome CFS/ME. PLoS ONE. 2018:13. [PMC free article: PMC5854315] [PubMed: 29543914]

20.

Stevens S, Snell C, Stevens J, Keller B, VanNess JM. Cardiopulmonary exercise test methodology for assessing exertion intolerance in myalgic encephalomyelitis/chronic fatigue syndrome. Front Pediatr. 2018;6:242. [PMC free article: PMC6131594] [PubMed: 30234078]

21.

Hodges LD, Nielsen T, Baken D. Physiological measures in participants with chronic fatigue syndrome, multiple sclerosis and healthy controls following repeated exercise: a pilot study. Clin Physiol Funct Imaging. 2018;38:639–44. [PubMed: 28782878]

22.

National Institute of Health. NIH ME/CFS Clinical Study. https://www​.nih.gov/mecfs​/nih-me-cfs-clinical-study; 2018.

23.

National Institute of Health. NIH announces centers for myalgic encephalomyelitis/chronic fatigue syndrome research. nih-announces-centers-myalgic-encephalomyelitis-chronic-fatigue-syndrome-research; 2018.

24.

Hardcastle SL, Brenu EW, Johnston S, Staines D, Marshall-Gradisnik S. Severity Scales for Use in Primary Health Care to Assess Chronic Fatigue Syndrome/Myalgic Encephalomyelitis. Health Care Women Int. 2016;37:671–86. [PubMed: 25315708]

25.

Castro-Marrero J, Faro M, Aliste L, Sáez-Francàs N, Calvo N, Martínez-Martínez A, et al. Comorbidity in chronic fatigue syndrome/myalgic encephalomyelitis: A nationwide population-based cohort study. Psychosomatics. 2017;58:533–43. [PubMed: 28596045]

26.

Nørregaard J BP, Prescott E, Jacobsen S, Danneskiold-Samsøe B. A four-year follow-up study in fibromyalgia. Relationship to chronic fatigue syndrome. Scand J Rheumatol. 1993;22:35–8. [PubMed: 8434245]

27.

Donnachie E, Schneider A, Mehring M, Enck P. Incidence of irritable bowel syndrome and chronic fatigue following GI infection: a population-level study using routinely collected claims data. Gut. 2018;67:1078–86. [PubMed: 28601847]

28.

Persson R WK, Hanevik K, Eide GE, Langeland N, Rortveit G. The relationship between irritable bowel syndrome, functional dyspepsia, chronic fatigue and overactive bladder syndrome: a controlled study 6 years after acute gastrointestinal infection. BMC Gastroenterol. 2015;10:66. [PMC free article: PMC4460696] [PubMed: 26058591]

29.

Maes M LJ, Geffard M, Berk M. vidence for the existence of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) with and without abdominal discomfort (irritable bowel) syndrome. Neuro Endocrinol Lett. 2014;35:445–53. [PubMed: 25433843]

30.

Mariman A, Delesie L, Tobback E, Hanoulle I, Sermijn E, Vermeir P, et al. Undiagnosed and comorbid disorders in patients with presumed chronic fatigue syndrome. J Psychosom Res. 2013;75:491–6. [PubMed: 24182640]

31.

Carruthers BM, van de Sande MI, De Meirleir KL, Klimas NG, Broderick G, Mitchell T, et al. Myalgic encephalomyelitis: International Consensus Criteria. J Intern Med. 2011;270:327–38. [PMC free article: PMC3427890] [PubMed: 21777306]

32.

Social Security Administration. Providing medical evidence for individuals with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). USA; 2018.

33.

Brurberg KG, Fonhus MS, Larun L, Flottorp S, Malterud K. Case definitions for chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME): a systematic review. BMJ Open. 2014;4:e003973. [PMC free article: PMC3918975] [PubMed: 24508851]

34.

Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med. 1994;121:953–9. [PubMed: 7978722]

35.

Carruthers BM JA, de Meirleir KL, Peterson DL, Klimas NG, Lerner AM, Bested AC, et al. Myalgic encephalomyelitis/chronic fatigue syndrome: Clinical working case definition, diagnostic and treatment protocols. J Chronic Fatigue Syndrome. 2003:11.

36.

Jason LA, Sunnquist M, Brown A, Newton JL, Strand EB, Vernon SD. Chronic Fatigue Syndrome versus Systemic Exertion Intolerance Disease. Fatigue. 2015;3:127–41. [PMC free article: PMC4556426] [PubMed: 26345409]

37.

Brown AA, Jason LA. Validating a measure of myalgic encephalomyelitis/chronic fatigue syndrome symptomatology. Fatigue. 2014;2:132–52. [PMC free article: PMC4871625] [PubMed: 27213118]

38.

Nacul LC, Lacerda EM, Pheby D, Campion P, Molokhia M, Fayyaz S, et al. Prevalence of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) in three regions of England: a repeated cross-sectional study in primary care. BMC Med. 2011;9:91. [PMC free article: PMC3170215] [PubMed: 21794183]

39.

Johnston SC, Staines DR, Marshall-Gradisnik SM. Epidemiological characteristics of chronic fatigue syndrome/myalgic encephalomyelitis in Australian patients. Clin Epidemiol. 2016;8:97–107. [PMC free article: PMC4878662] [PubMed: 27279748]

40.

Newton JL MH, Scott A, Hoad A, Spickett G. The Newcastle NHS Chronic Fatigue Syndrome Service: not all fatigue is the same. J R Coll Physicians Edinb. 2010;40:304–7. [PubMed: 21132135]

41.

Devasahayam A, Lawn T, Murphy M, White PD. Alternative diagnoses to chronic fatigue syndrome in referrals to a specialist service: service evaluation survey. JRSM Short Rep. 2012;3:4. [PMC free article: PMC3269106] [PubMed: 22299071]

42.

Socialstyrelsen. Utmattningssyndrom – Stressrelaterad psykisk ohälsa; 2003.

43.

Grossi G, Perski A, Osika W, Savic I. Stress-related exhaustion disorder--clinical manifestation of burnout? A review of assessment methods, sleep impairments, cognitive disturbances, and neuro-biological and physiological changes in clinical burnout. Scand J Psychol. 2015;56:626–36. [PubMed: 26496458]

44.

Besèr A SK, Wahlberg K, Peterson U, Nygren A, Asberg M. Construction and evaluation of a self rating scale for stress-induced exhaustion disorder, the Karolinska Exhaustion Disorder Scale. Scand J Psychol. 2014;55:72–82. [PMC free article: PMC4235404] [PubMed: 24236500]

45.

Wallensten J, Asberg M, Nygren A, Szulkin R, Wallen H, Mobarrez F, et al. Possible Biomarkers of Chronic Stress Induced Exhaustion – A Longitudinal Study. PLoS One. 2016;11:e0153924. [PMC free article: PMC4856355] [PubMed: 27145079]

46.

Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum. 1990;33:160–72. [PubMed: 2306288]

47.

Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Hauser W, Katz RL, et al. 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria. Semin Arthritis Rheum. 2016;46:319–29. [PubMed: 27916278]

48.

Sharpe MC, Archard LC, Banatvala JE, Borysiewicz LK, Clare AW, David A, et al. A report--chronic fatigue syndrome: guidelines for research. J R Soc Med. 1991;84:118–21. [PMC free article: PMC1293107] [PubMed: 1999813]

49.

Furberg H, Olarte M, Afari N, Goldberg J, Buchwald D, Sullivan PF. The prevalence of self-reported chronic fatigue in a U.S. twin registry. J Psychosom Res. 2005;59:283–90. [PMC free article: PMC2949064] [PubMed: 16253618]

50.

Rusu C, Gee ME, Lagace C, Parlor M. Chronic fatigue syndrome and fibromyalgia in Canada: prevalence and associations with six health status indicators. Health Promot Chronic Dis Prev Can. 2015;35:3–11. [PMC free article: PMC4939456] [PubMed: 25811400]

51.

Socialstyrelsen. Internationell statistisk klassifikation av sjukdomar och relaterade hälsoproblem. Systematisk förteckning Svensk version 2016. Del 1 (3). Svensk version av International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10). http://apps​.who.int/iris​/bitstream/handle​/10665/246208/9789175553801-V1-part1-swe​.pdf;jsessionid=0AE99E57D5CFA82F4BDE0AFD017A2440?sequence​=11; 2016.

52.

Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8:336–41. [PubMed: 20171303]

53.

Tong A, Flemming K, McInnes E, Oliver S, Craig J. Enhancing transparency in reporting the synthesis of qualitative research: ENTREQ. BMC Med Res Methodol. 2012;12:181. [PMC free article: PMC3552766] [PubMed: 23185978]

54.

Statens beredning för medicinsk och social utvärdering (SBU). SBU:s handbok: Utvärdering av metoder i hälso-och sjukvården och insatser i socialtjänsten. Stockholm; 2017.

55.

Sterne JA, Hernan MA, Reeves BC, Savovic J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. [PMC free article: PMC5062054] [PubMed: 27733354]

56.

Thomas J, Harden A. Methods for the thematic synthesis of qualitative research in systematic reviews. BMC Med Res Methodol. 2008;8:45. [PMC free article: PMC2478656] [PubMed: 18616818]

57.

Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64:383–94. [PubMed: 21195583]

58.

Lewin S GC, Munthe-Kaas H, Carlsen B, Colvin CJ, Gulmezoglu M, Noves J, et al. Using qualitative evidence in decision making for health and social interventions: an approach to assess confidence in findings from qualitative evidence syntheses. PLoS Med. 2015:12. [PMC free article: PMC4624425] [PubMed: 26506244]

59.

Munthe-Kaas H, Bohren MA, Glenton C, Lewin S, Noyes J, Tuncalp O, et al. Applying GRADE-CERQual to qualitative evidence synthesis findings-paper 3: how to assess methodological limitations. Implement Sci. 2018;13:9. [PMC free article: PMC5791044] [PubMed: 29384078]

60.

Colvin CJ, Garside R, Wainwright M, Munthe-Kaas H, Glenton C, Bohren MA, et al. Applying GRADE-CERQual to qualitative evidence synthesis findings-paper 4: how to assess coherence. Implement Sci. 2018;13:13. [PMC free article: PMC5791039] [PubMed: 29384081]

61.

Noyes J, Booth A, Lewin S, Carlsen B, Glenton C, Colvin CJ, et al. Applying GRADE-CERQual to qualitative evidence synthesis findings-paper 6: how to assess relevance of the data. Implement Sci. 2018;13:4. [PMC free article: PMC5791042] [PubMed: 29384080]

62.

Glenton C, Carlsen B, Lewin S, Munthe-Kaas H, Colvin CJ, Tuncalp O, et al. Applying GRADE-CERQual to qualitative evidence synthesis findings-paper 5: how to assess adequacy of data. Implement Sci. 2018;13:14. [PMC free article: PMC5791045] [PubMed: 29384077]

63.

Montoya JG, Kogelnik AM, Bhangoo M, Lunn MR, Flamand L, Merrihew LE, et al. Randomized clinical trial to evaluate the efficacy and safety of valganciclovir in a subset of patients with chronic fatigue syndrome. J Med Virol. 2013;85:2101–9. [PubMed: 23959519]

64.

Nilsson MKL, Zachrisson O, Gottfries CG, Matousek M, Peilot B, Forsmark S, et al. A randomised controlled trial of the monoaminergic stabiliser (−)-OSU6162 in treatment of myalgic encephalomyelitis/chronic fatigue syndrome. Acta Neuropsychiatrica. 2017:1–10. [PubMed: 29212562]

65.

Pinxsterhuis I, Sandvik L, Strand EB, Bautz-Holter E, Sveen U. Effectiveness of a group-based self-management program for people with chronic fatigue syndrome: a randomized controlled trial. Clin Rehabil. 2017;31:93–103. [PubMed: 26672998]

66.

Witham MD, Adams F, McSwiggan S, Kennedy G, Kabir G, Belch JJF, et al. Effect of intermittent vitamin D3 on vascular function and symptoms in chronic fatigue syndrome--a randomised controlled trial. Nutr Metab Cardiovasc Dis. 2015;25:287–94. [PubMed: 25455721]

67.

Friedberg F, Adamowicz J, Caikauskaite I, Seva V, Napoli A. Efficacy of two delivery modes of behavioral self-management in severe chronic fatigue syndrome. Fatigue. 2016;4:158–74.

68.

Hall DL, Lattie EG, Milrad SF, Czaja S, Fletcher MA, Klimas N, et al. Telephone-administered versus live group cognitive behavioral stress management for adults with CFS. J Psychosom Res. 2017;93:41–7. [PMC free article: PMC5270375] [PubMed: 28107891]

69.

Nunez M F-SJ, Nunez E, Fernandez-Huerta JM, Godas-Sieso T, Gomez-Gil E. Health-related quality of life in patients with chronic fatigue syndrome: group cognitive behavioural therapy and graded exercise versus usual treatment. A randomised controlled trial with 1 year of follow-up. Clin Rheumatol. 2011;30:381–9. [PubMed: 21234629]

70.

Clark LV, Pesola F, Thomas JM, Vergara-Williamson M, Beynon M, White PD. Guided graded exercise self-help plus specialist medical care versus specialist medical care alone for chronic fatigue syndrome (GETSET): a pragmatic randomised controlled trial. Lancet (London, England). 2017;390:363–73. [PMC free article: PMC5522576] [PubMed: 28648402]

71.

Fernie BA, Murphy G, Wells A, Nikcevic AV, Spada MM. Treatment outcome and metacognitive change in CBT and GET for chronic fatigue syndrome. Behav Cogn Psychother. 2016;44:397–409. [PubMed: 25895437]

72.

Kos D, van Eupen I, Meirte J, Van Cauwenbergh D, Moorkens G, Meeus M, et al. Activity pacing self-management in chronic fatigue syndrome: A randomized controlled trial. Am J Occup Ther. 2015;69:6905290020. [PMC free article: PMC4564796] [PubMed: 26356665]

73.

Marques MM, de Gucht V, Leal I, Maes S. Efficacy of a randomized controlled self-regulation based physical activity intervention for chronic fatigue: Mediation effects of physical activity progress and self-regulation skills. J Psychosom Res. 2017;94:24–31. [PubMed: 28183399]

74.

Moss-Morris R, Sharon C, Tobin R, Baldi JC. A randomized controlled graded exercise trial for chronic fatigue syndrome: outcomes and mechanisms of change. J Health Psychol. 2005;10:245–59. [PubMed: 15723894]

75.

Wallman KE, Morton AR, Goodman C, Grove R, Guilfoyle AM. Randomised controlled trial of graded exercise in chronic fatigue syndrome. Med J Aust. 2004;180:444–8. [PubMed: 15115421]

76.

White P, Chalder T, Sharpe M. The PACE trial: Results of a large trial of nonpharmacological treatments. J Psychosom Res. 2011;70:622.

77.

Burgess M, Andiappan M, Chalder T. Cognitive behaviour therapy for chronic fatigue syndrome in adults: face to face versus telephone treatment: a randomized controlled trial. Behav Cogn Psychother. 2012;40:175–91. [PubMed: 21929831]

78.

Friedberg F, Napoli A, Coronel J, Adamowicz J, Seva V, Caikauskaite I, et al. Chronic fatigue self-manage-ment in primary care: a randomized trial. Psychosom Med. 2013;75:650–7. [PMC free article: PMC3785003] [PubMed: 23922399]

79.

Hlavaty LE, Brown MM, Jason LA. The effect of homework compliance on treatment outcomes for participants with myalgic encephalomyelitis/chronic fatigue syndrome. Rehabil Psychol. 2011;56:212–8. [PMC free article: PMC3166212] [PubMed: 21767035]

80.

Janse A, Worm-Smeitink M, Bleijenberg G, Donders R, Knoop H. Efficacy of web-based cognitive-behavioural therapy for chronic fatigue syndrome: randomised controlled trial. Br J Psychiatry. 2018;212:112–8. [PubMed: 29436329]

81.

Knoop H, Van Der Meer JWM, Bleijenberg G. Guided self-instructions for people with chronic fatigue syndrome: Randomised controlled trial. Br J Psychiatry. 2008;193:340–1. [PubMed: 18827302]

82.

O’Dowd H, Gladwell P, Rogers CA, Hollinghurst S, Gregory A. Cognitive behavioural therapy in chronic fatigue syndrome: A ramdomised controlled trial of an outpatient group programme. Health Technology Assessment. 2006;10:iii-51. [PubMed: 17014748]

83.

Rimes K, Wingrove J. Mindfulness-based cognitive therapy for people with chronic fatigue syndrome still experiencing excessive fatigue after cognitive behaviour therapy: a pilot randomized study. Clin Psychol Psychother. 2013;20:107–17. In. [PubMed: 21983916]

84.

Wearden AJ, Dowrick C, Chew-Graham C, Bentall RP, Morriss RK, Peters S, et al. Nurse led, home based self help treatment for patients in primary care with chronic fatigue syndrome: Randomised controlled trial. BMJ (Online). 2010;340:959. [PMC free article: PMC2859122] [PubMed: 20418251]

85.

Wiborg JF, van Bussel J, van Dijk A, Bleijenberg G, Knoop H. Randomised controlled trial of cognitive behaviour therapy delivered in groups of patients with chronic fatigue syndrome. Psychother Psychosom. 2015;84:368–76. [PubMed: 26402868]

86.

Windthorst P, Mazurak N, Kuske M, Hipp A, Giel KE, Enck P, et al. Heart rate variability biofeedback therapy and graded exercise training in management of chronic fatigue syndrome: An exploratory pilot study. J Psychosom Res. 2017;93:6–13. [PubMed: 28107894]

87.

Vos-Vromans DCWM, Smeets RJEM, Huijnen IPJ, Köke AJA, Hitters WMGC, Rijnders LJM, et al. Multidisciplinary rehabilitation treatment versus cognitive behavioural therapy for patients with chronic fatigue syndrome: A randomized controlled trial. J Intern Med. 2016;279:268–82. [PubMed: 26306716]

88.

Tummers M, Knoop H, Bleijenberg G. Effectiveness of stepped care for chronic fatigue syndrome: a randomized noninferiority trial. J Consult Clin Psychol. 2010;78:724–31. [PubMed: 20873907]

89.

Arnold LM, Blom TJ, Welge JA, Mariutto E, Heller A. A randomized, placebo-controlled, double-blinded trial of duloxetine in the treatment of general fatigue in patients with chronic fatigue syndrome. Psychosomatics. 2015;56:242–53. [PubMed: 25660434]

90.

Fluge O, Bruland O, Risa K, Storstein A, Kristoffersen EK, Sapkota D, et al. Benefit from B-lymphocyte depletion using the anti-CD20 antibody rituximab in chronic fatigue syndrome. A double-blind and placebo-controlled study. PloS one. 2011;6:e26358. [PMC free article: PMC3198463] [PubMed: 22039471]

91.

Montoya JG, Anderson JN, Adolphs DL, Bateman L, Klimas N, Levine SM, et al. KPAX002 as a treatment for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): A prospective, randomized trial. Int J Clin Exp Med. 2018;11:2890–900.

92.

Pardini M, Guida S, Primavera A, Krueger F, Cocito L, Gialloreti LE. Amisulpride vs. fluoxetine treatment of Chronic Fatigue Syndrome: A pilot study. Eur Neuropsychopharmacol. 2011;21:282–6. [PubMed: 21112746]

93.

Roerink ME, Bredie SJH, Heijnen M, Dinarello CA, Knoop H, Van der Meer JWM. Cytokine Inhibition in Patients With Chronic Fatigue Syndrome: A Randomized Trial. Ann Intern Med. 2017;166:557–64. [PubMed: 28265678]

94.

Strayer DR, Carter WA, Stouch BC, Stevens SR, Bateman L, Cimoch PJ, et al. A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome. PloS one. 2012;7:e31334. [PMC free article: PMC3303772] [PubMed: 22431963]

95.

The GK. Bleijenberg G, Buitelaar JK, van der Meer JW. The effect of ondansetron, a 5-HT3 receptor antagonist, in chronic fatigue syndrome: a randomized controlled trial. J Clin Psychiatry. 2010;71:528–33. [PubMed: 20122367]

96.

Castro-Marrero J, Cordero MD, Segundo MJ, Sáez-Francàs N, Calvo N, Román-Malo L, et al. Does oral coenzyme Q10 plus NADH supplementation improve fatigue and biochemical parameters in chronic fatigue syndrome? Antioxid Redox Signal. 2015;22:679–85. [PMC free article: PMC4346380] [PubMed: 25386668]

97.

Fukuda S, Nojima J, Kajimoto O, Yamaguti K, Nakatomi Y, Kuratsune H, et al. Ubiquinol-10 supplementation improves autonomic nervous function and cognitive function in chronic fatigue syndrome. BioFactors. 2016;42:431–40. [PubMed: 27125909]

98.

Ostojic SM, Stojanovic M, Drid P, Hoffman JR, Sekulic D, Zenic N. Supplementation with guanidinoacetic acid in women with Chronic Fatigue Syndrome. Nutrients. 2016;8:72. [PMC free article: PMC4772036] [PubMed: 26840330]

99.

Chan JSM, Ho RTH, Wang C-W, Yuen LP, Sham JST, Chan CLW. Effects of qigong exercise on fatigue, anxiety, and depressive symptoms of patients with chronic fatigue syndrome-like illness: a randomized controlled trial. Evid Based Complement Alternat Med. 2013;2013:485341. [PMC free article: PMC3747479] [PubMed: 23983785]

100.

Kim HG, Cho JH, Yoo SR, Lee JS, Han JM, Lee NH, et al. Antifatigue Effects of Panax ginseng C.A. Meyer: A randomised, double-blind, placebo-controlled Trial. PLoS ONE. 2013:8. [PMC free article: PMC3629193] [PubMed: 23613825]

101.

Kim J-E, Seo B-K, Choi J-B, Kim H-J, Kim T-H, Lee M-H, et al. Acupuncture for chronic fatigue syndrome and idiopathic chronic fatigue: a multicenter, nonblinded, randomized controlled trial. Trials. 2015;16:314. [PMC free article: PMC4515016] [PubMed: 26211002]

102.

Li D, Li Z, Dai Z. Selective serotonin reuptake inhibitor combined with dengzhanshengmai capsule improves the fatigue symptoms: a 12-week open-label pilot study. Int J Clin Exp Med. 2015;8:11811–7. [PMC free article: PMC4565405] [PubMed: 26380022]

103.

Ng SM, Yiu YM. Acupuncture for chronic fatigue syndrome: a randomized, sham-controlled trial with single-blinded design. Altern Ther Health Med. 2013;19:21–6. [PubMed: 23981369]

104.

Jason LA, Roesner N, Porter N, Parenti B, Mortensen J, Till L. Provision of social support to individuals with chronic fatigue syndrome. J Clin Psychol. 2010;66:249–58. [PMC free article: PMC3693568] [PubMed: 19902489]

105.

Huibers MJH, Beurskens AJHM, Van Schayck CP, Bazelmans E, Metsemakers JFM, Knottnerus JA, et al. Efficacy of cognitive-behavioural therapy by general practitioners for unexplained fatigue among employees: Randomised controlled trial. Br J Psychiatry. 2004;184:240–6. [PubMed: 14990522]

106.

Huibers MJH, Bultmann U, Kasl SV, Kant I, van Amelsvoort LGPM, van Schayck CP, et al. Predicting the two-year course of unexplained fatigue and the onset of long-term sickness absence in fatigued employees: results from the Maastricht Cohort Study. J Occup Environ Med. 2004;46:1041–7. [PubMed: 15602178]

107.

Collin SM, Crawley E, May MT, Sterne JAC, Hollingworth W, Database UCMNO. The impact of CFS/ME on employment and productivity in the UK: a cross-sectional study based on the CFS/ME national outcomes database. BMC Health Serv Res. 2011;11:217. [PMC free article: PMC3184626] [PubMed: 21923897]

108.

Tritt K, Nickel M, Mitterlehner F, Nickel C, Forthuber P, Leiberich P, et al. Chronic fatigue and indicators of long-term employment disability in psychosomatic inpatients. Wien Klin Wochenschr. 2004;116:182–9. [PubMed: 15088993]

109.

Roche R TR. Coping and occupational participation in chronic fatigue syndrome. OTJR (Thorofare N J). 2005:25.

110.

Houlton A, Christie MM, Smith B, Gardiner E. Long-term follow-up of multi-disciplinary outpatient treatment for chronic fatigue syndrome/myalgic encephalopathy. Fatigue. 2015;3:47–58.

111.

Meeus M, Nijs J, Van Mol E, Truijen S, De Meirleir K. Role of psychological aspects in both chronic pain and in daily functioning in chronic fatigue syndrome: a prospective longitudinal study. Clin Rheumatol. 2012;31:921–9. [PubMed: 22349876]

112.

Flo E, Chalder T. Prevalence and predictors of recovery from chronic fatigue syndrome in a routine clinical practice. Behav Res The. 2014;63:1–8. [PubMed: 25222752]

113.

Crawley E, Collin SM, White PD, Rimes K, Sterne JAC, May MT, et al. Treatment outcome in adults with chronic fatigue syndrome: a prospective study in England based on the CFS/ME National Outcomes Database. QJM. 2013;106:555–65. [PMC free article: PMC3665909] [PubMed: 23538643]

114.

Huibers MJH, Bleijenberg G, van Amelsvoort LGPM, Beurskens AJHM, van Schayck CP, Bazelmans E, et al. Predictors of outcome in fatigued employees on sick leave: results from a randomised trial. J Psychosom Res. 2004;57:443–9. [PubMed: 15581647]

115.

Huibers MJH, Leone SS, Kant IJ, Knottnerus JA. Chronic fatigue syndrome-like caseness as a predictor of work status in fatigued employees on sick leave: four year follow up study. Occup Environ Med. 2006;63:570–2. [PMC free article: PMC2078121] [PubMed: 16698810]

116.

Leone SS, Huibers MJH, Kant I, Van Schayck CP, Bleijenberg G, Knottnerus JA. Long-term predictors of outcome in fatigued employees on sick leave: A 4-year follow-up study. Psychol Med. 2006;36:1293–1300. [PubMed: 16753082]

117.

Nyland M, Naess H, Birkeland JS, Nyland H. Longitudinal follow-up of employment status in patients with chronic fatigue syndrome after mononucleosis. BMJ open. 2014;4:e005798. [PMC free article: PMC4248085] [PubMed: 25428629]

118.

Jason LA, Porter N, Hunnell J, Rademaker A, Richman JA. CFS prevalence and risk factors over time. J Health Psychol. 2011;16:445–56. [PMC free article: PMC3166209] [PubMed: 21224330]

119.

Andersen MM, Permin H, Albrecht F. Illness and disability in Danish Chronic Fatigue Syndrome patients at diagnosis and 5-year follow-up. J Psychosom Res. 2004;56:217–29. [PubMed: 15016582]

120.

Brown MM, Bell DS, Jason LA, Christos C, Bell DE. Understanding long‐term outcomes of chronic fatigue syndrome. J Clin Psychol. 2012;68:1028–35. [PMC free article: PMC3940158] [PubMed: 22753044]

121.

McDermott C, Richards SCM, Ankers S, Selby M, Harmer J, Moran CJ. An evaluation of a chronic fatigue lifestyle management programme focusing on the outcome of return to work or training. Br J Occup Ther. 2004;67:269–73.

122.

Cairns R, Hotopf M. A systematic review describing the prognosis of chronic fatigue syndrome. Occup Med (Lond). 2005;55:20–31. [PubMed: 15699087]

123.

Bombardier CH, Buchwald D. Outcome and prognosis of patients with chronic fatigue vs chronic fatigue syndrome. Arch Intern Med. 1995;155:2105–10. [PubMed: 7575071]

124.

Tiersky LA DJ, Hill N, Dhar SK, Johnson SK, Lange G, Rappolt G, Natelson BH. Longitudinal assessment of neuropsychological functioning, psychiatric status, functional disability and employment status in chronic fatigue syndrome. Appl Neuropsychol. 2001;8:41–50. [PubMed: 11388123]

125.

Arroll MA, Senior V. Individuals’ experience of chronic fatigue syndrome/myalgic encephalomyelitis: an interpretative phenomenological analysis. Psychol Health. 2008;23:443–58. [PubMed: 25160578]

126.

Brooks J, King N, Wearden A. Couples’ experiences of interacting with outside others in chronic fatigue syndrome: a qualitative study. Chronic Illn. 2014;10:5–17. [PubMed: 23585635]

127.

Broughton J, Harris S, Beasant L, Crawley E, Collin SM. Adult patients’ experiences of NHS specialist services for chronic fatigue syndrome (CFS/ME): a qualitative study in England. BMC Health Serv Res. 2017;17:384. [PMC free article: PMC5457632] [PubMed: 28576141]

128.

de Carvalho Leite JC. Social support needs for equity in health and social care: a thematic analysis of experiences of people with chronic fatigue syndrome/myalgic encephalomyelitis. Int J Equity Health. 2011;10:46. de L Drachler M, Killett A, Kale S, Nacul L, McArthur M, et al. [PMC free article: PMC3229491] [PubMed: 22044797]

129.

Edwards CR, Thompson AR, Blair A. An ‘overwhelming illness’: women’s experiences of learning to live with chronic fatigue syndrome/myalgic encephalomyelitis. J Health Psychol. 2007;12:203–14. [PubMed: 17284485]

130.

Gilje AM, Soderlund A, Malterud K. Obstructions for quality care experienced by patients with chronic fatigue syndrome (CFS)--a case study. Patient Educ Couns. 2008;73:36–41. [PubMed: 18486415]

131.

Hannon K, Peters S, Fisher L, Riste L, Wearden A, Lovell K, et al. Developing resources to support the diagnosis and management of Chronic Fatigue Syndrome/Myalgic Encephalitis (CFS/ME) in primary care: a qualitative study. BMC Fam Pract. 2012;13:93. [PMC free article: PMC3573921] [PubMed: 22998151]

132.

Larun L, Malterud K. Finding the right balance of physical activity: a focus group study about experiences among patients with chronic fatigue syndrome. Patient Educ Couns. 2011;83:222–6. [PubMed: 20580520]

133.

McDermott C, Lynch J, Leydon GM. Patients’ hopes and expectations of a specialist chronic fatigue syndrome/ME service: a qualitative study. Fam Pract. 2011;28:572–8. [PubMed: 21555341]

134.

Ryckeghem H, Delesie L, Tobback E, Lievens S, Vogelaers D, Mariman A. Exploring the potential role of the advanced nurse practitioner within a care path for patients with chronic fatigue syndrome. J Adv Nurs. 2017;73:1610–9. [PubMed: 28000331]

135.

Stormorken E, Jason LA, Kirkevold M. Factors impacting the illness trajectory of post-infectious fatigue syndrome: a qualitative study of adults’ experiences. BMC Public Health. 2017;17:952. [PMC free article: PMC5729235] [PubMed: 29237442]

136.

Picariello F, Ali S, Foubister C, Chalder T. ‘It feels sometimes like my house has burnt down, but I can see the sky’: A qualitative study exploring patients’ views of cognitive behavioural therapy for chronic fatigue syndrome. Br J Health Psychol. 2017;22:383–413. [PubMed: 28349621]

137.

Pemberton S, Cox DL. Experiences of daily activity in chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) and their implications for rehabilitation programmes. Disabil Rehabil. 2014;36:1790–7. [PubMed: 24369769]

138.

Son H-M, Park EY, Kim DH, Kim E, Shin M-S, Kim T-H. Experiences with, perceptions of and attitudes towards traditional Korean medicine (TKM) in patients with chronic fatigue: a qualitative, one-on-one, in-depth interview study. BMJ Open. 2015;5:e006178. [PMC free article: PMC4563217] [PubMed: 26351179]

139.

Cornes O. Chronic fatigue syndrome: a patient’s perspective. Br J Gen Pract. 2013;63:648. [PMC free article: PMC3839372] [PubMed: 24351479]

140.

Childs N, Robinson L, Chowdhury S, Ogden C, Newton JL. Consulting patients in setting priorities in Myalgic Encephalomyelitis (M.E.) research: findings from a national on-line survey. Res Involv Engagem. 2015;1:11. [PMC free article: PMC5611561] [PubMed: 29062500]

141.

Guise J, McVittie C, McKinlay A. A discourse analytic study of ME/CFS (Chronic Fatigue Syndrome) sufferers’ experiences of interactions with doctors. J Health Psychol. 2010;15:426–35. [PubMed: 20348363]

142.

Hansen AH, Lian OS. Experiences of general practitioner continuity among women with chronic fatigue syndrome/myalgic encephalomyelitis: a cross-sectional study. BMC Health Serv Res. 2016;16:650. [PMC free article: PMC5109710] [PubMed: 27842587]

143.

Hansen AH, Lian OS. How do women with chronic fatigue syndrome/myalgic encephalomyelitis rate quality and coordination of healthcare services? A cross-sectional study. BMJ Open. 2016;6:e010277. [PMC free article: PMC4823449] [PubMed: 27044578]

144.

Lian OS, Hansen AH. Factors facilitating patient satisfaction among women with medically unexplained long-term fatigue: A relational perspective. Health (London, England : 1997) 2016;20:308-26. [PubMed: 25979224]

145.

Lian OS, Robson C. “It’s incredible how much I’ve had to fight.” Negotiating medical uncertainty in clinical encounters. Int J Qual Stud Health Well-being. 2017;12:1392219. [PMC free article: PMC5654014] [PubMed: 29063801]

146.

Van Hoof E. The doctor-patient relationship in chronic fatigue syndrome: survey of patient perspectives. Qual Prim Care. 2009;17:263–70. [PubMed: 19807959]

147.

Malterud K. Systematic text condensation: a strategy for qualitative analysis. Scand J Public Health. 2012;40:795–805. [PubMed: 23221918]

148.

Zachrisson O, Regland B, Jahreskog M, Jonsson M, Kron M, Gottfries CG. Treatment with staphylococcus toxoid in fibromyalgia/chronic fatigue syndrome--a randomised controlled trial. Eur J Pain. 2002;6:455–66. [PubMed: 12413434]

149.

Kaslow JE, Rucker L, Onishi R. Liver extract-folic acid-cyanocobalamin vs placebo for chronic fatigue syndrome. Arch Intern Med. 1989;149:2501–3. [PubMed: 2684076]

150.

Regland B, Forsmark S, Halaouate L, Matousek M, Peilot B, Zachrisson O, et al. Response to vitamin B12 and folic acid in myalgic encephalomyelitis and fibromyalgia. PloS One. 2015;10:e0124648. [PMC free article: PMC4406448] [PubMed: 25902009]

151.

Ljungar I, Hagman S, Wernegren H. Slutrapport av ME/CFS-projektet (Myalgisk Encefalomyelit/Chronic Fatigue Syndrom) Stockholm: Rehabiliteringsmedicinska Universitetskliniken Stockholm. 2013.

152.

Drachler Mde L, Leite JC, Hooper L, Hong CS, Pheby D, Nacul L, et al. The expressed needs of people with chronic fatigue syndrome/myalgic encephalomyelitis: a systematic review. BMC Public Health. 2009;9:458. [PMC free article: PMC2799412] [PubMed: 20003363]

153.

Larsson J, Lilliebjörk A. Chronic Fatigue Syndrome – the patients experiences of their health condition and multidisciplinary treatment. Karolinska Institutet. Avdelningen för neurobiologi, vårdvetenskap och samhälle. Stockholm; 2012.

154.

Bayliss K, Goodall M, Chisholm A, Fordham B, Chew-Graham C, Riste L, et al. Overcoming the barriers to the diagnosis and management of chronic fatigue syndrome/ME in primary care: a meta synthesis of qualitative studies. BMC Fam Pract. 2014;15:44. [PMC free article: PMC3973969] [PubMed: 24606913]

155.

Asbring P, Narvanen AL. Ideal versus reality: physicians perspectives on patients with chronic fatigue syndrome (CFS) and fibromyalgia. Soc Sci Med. 2003;57:711–20. [PubMed: 12821018]

Project group

Appendix 1 Search strategies

Download PDF (1.1M)

Appendix 2 Excluded studies

Download PDF (920K)

Appendix 3 Charachteristics of included studies

Download PDF (639K)